Two clinical trials presented at the European Cystic Fibrosis Conference

https://globenewswire.com/news-release/2017/08/17/1088301/0/en/Fluidigm-Licenses-CFTR-Next-Generation-Sequencing-Assay-From-Baylor-Genetics-for-Use-With-the-Juno-System.html

ProQR Announces Results for the Second Quarter of 2017

Key updates
• Data from two clinical trials of QR-010 presented at the European Cystic Fibrosis Conference. Enrollment completed in the Phase 1b clinical trial in cystic Continue reading Two clinical trials presented at the European Cystic Fibrosis Conference

Results for Phase 3 Clinical Study to Treat Exocrine Pancreatic Insufficiency

https://globenewswire.com/news-release/2017/08/14/1084291/0/en/Anthera-Pharmaceuticals-Announces-RESULT-Phase-3-Clinical-Study-of-Sollpura-will-be-Included-in-the-European-Cystic-Fibrosis-Clinical-Trial-Network.html

Anthera Pharmaceuticals Announces RESULT Phase 3 Clinical Study of Sollpura will be Included in the European Cystic Fibrosis Clinical Trial Network

Anthera Pharmaceuticals (Nasdaq:ANTH) today announced that the RESULT Continue reading Results for Phase 3 Clinical Study to Treat Exocrine Pancreatic Insufficiency

Phase Two Clinical Trials to treat NTM

http://www.nasdaq.com/press-release/ait-therapeutics-announces-enrollment-of-first-patient-into-its-nontm-abscessus-phase-2-trial-in-20170807-00641

AIT Therapeutics Announces Enrollment of First Patient into Its NO-NTM abscessus Phase 2 Trial in Nontuberculous Mycobacteria (NTM)

10 patients with Mycobacterium Abscessus Complex (MABSC) are expected to enroll in the trial Continue reading Phase Two Clinical Trials to treat NTM

Cystic Fibrosis Evolution

https://www.news-medical.net/health/Cystic-Fibrosis-Evolution.aspx

Cystic fibrosis is the most common genetic disease among people of European descent. It is an autosomal recessive disorder caused by a mutation of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. When a Continue reading Cystic Fibrosis Evolution

News on new drug to treat B. Cepacia

https://cysticfibrosisnewstoday.com/2017/07/31/synspira-snsp113-may-be-game-changer-cf-cystic-fibrosis-drug-resistant-bacteria/

Originally published on Cystic Fibrosis Today Website 7/31/17
By Reid D’Amico

Synspira’s CF Therapy May Be Game-Changer for Drug-Resistant Bacteria

Chronic pulmonary infections are a hallmark of lung disease in patients with cystic fibrosis. Due to the variability in bacteria that can colonize the lung and Continue reading News on new drug to treat B. Cepacia

New Drug Application Submitted for Treatment of P. aeruginosa

https://bronchiectasisnewstoday.com/2017/07/28/non-cystic-fibrosis-bronchiectasis-candidate-therpay-nda-submitted-for-linhaliq-for-p-aeruginosa-infection/

New Drug Application Submitted for Linhaliq as Treatment of Pseudomonas Aeruginosa Infection in NCFBE Patients

The pharmaceutical company Aradigm has submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for Linhaliq Continue reading New Drug Application Submitted for Treatment of P. aeruginosa

French Biotech Receives an Award to Develop a Novel Cystic Fibrosis Antibiotic

https://labiotech.eu/antabio-carb-x-cystic-fibrosis/

CARB-X has awarded $8.9M (€7.6M) to Antabio for the development of a new antibiotic against resistant Pseudomonas infections in cystic fibrosis patients.

Antabio is a French company developing new antibiotics to fight the rapidly Continue reading French Biotech Receives an Award to Develop a Novel Cystic Fibrosis Antibiotic

New cystic fibrosis biotech aims to take a different approach than Vertex

http://www.bizjournals.com/

California-based Synedgen has spun out its experimental cystic fibrosis treatments into a new biotech to be based in the Boston area, with an eye toward complementing existing drugs for the lung disease. Continue reading New cystic fibrosis biotech aims to take a different approach than Vertex

Phase 2 Trial of Its Nitric Oxide Product as Cystic Fibrosis Treatment

Novoteris to Start Phase 2 Trial of Its Nitric Oxide Product Thiolanox as Cystic Fibrosis Treatment

https://cysticfibrosisnewstoday.com/2017/06/06/novoteris-to-start-phase-2-trial-of-its-nitric-oxide-therapy-thiolanux-for-cystic-fibrosis/?utm_source=Cystic+Fibrosis&utm_campaign=64d2239573-RSS_MONDAY_EMAIL_CAMPAIGN&utm_medium=email&utm_term=0_b075749015-64d2239573-71418393

by Daniela Semedo, PhD, In Cystic Fibrosis News Today

Continue reading Phase 2 Trial of Its Nitric Oxide Product as Cystic Fibrosis Treatment

First Cystic Fibrosis Patients in U.S. Arm of Phase 2a Clinical Trial Receive RPL554

https://cysticfibrosisnewstoday.com/2017/06/08/cystic-fibrosis-patients-in-american-arm-of-phase-2a-trial-begin-receiving-rpl554/?utm_source=Cystic+Fibrosis&utm_campaign=64d2239573-RSS_MONDAY_EMAIL_CAMPAIGN&utm_medium=email&utm_term=0_b075749015-64d2239573-71418393

Cystic fibrosis patients in the United States have begun receiving the anti-inflammatory and airway-opening agent RPL554 in a Phase 2a clinical Continue reading First Cystic Fibrosis Patients in U.S. Arm of Phase 2a Clinical Trial Receive RPL554